TRML VS NVO Stock Comparison

Performance

TRML
100/100

TRML returned 56.10% in the last 12 months. Based on SPY's performance of 13.09%, its performance is above average giving it a score of 100 of 100.

NVO
100/100

NVO returned 70.22% in the last 12 months. Based on SPY's performance of -13.73%, its performance is above average giving it a score of 100 of 100.

Volatility

TRML
67/100

TRML has had a higher than average amount of volatility over the last 12 months giving it a score of 66 of 100.

NVO
53/100

NVO has had a higher than average amount of volatility over the last 12 months giving it a score of 52 of 100.

Analyst Price Targets

TRML

"Analyst Price Targets" not found for TRML

NVO
50/100

1 analysts offer 12-month price targets for NVO. Together, they have an average target of 0, the most optimistic target put NVO at 0 within 12-months and the most pessimistic has NVO at 0.

Technicals

TRML

"Technicals" not found for TRML

NVO
50/100

NVO receives a 50 of 100 based on 14 indicators. 6 are bullish, 6 are bearish.

Earnings

TRML

"Earnings" not found for TRML

NVO
46/100

NVO has missed earnings 3 times in the last 20 quarters.

Profit

TRML

"Profit" not found for TRML

NVO
90/100

Out of the last 20 quarters, NVO has had 20 profitable quarters and has increased their profits year over year on 15 of them.

All score calculations are broken down here to help you make more informed investing decisions

Tourmaline Bio, Inc. Common Stock Summary

Nasdaq / TRML

Healthcare

Biotechnology

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.

Novo-Nordisk A/S Summary

New York Stock Exchange / NVO

Healthcare

Biotechnology

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Power up your portfolio